Vaccinia virus-based vector against infectious diseases and tumors

Hum Vaccin Immunother. 2021 Jun 3;17(6):1578-1585. doi: 10.1080/21645515.2020.1840887. Epub 2021 Feb 19.

Abstract

Vaccinia virus was used to prevent smallpox. After the World Health Organization declared smallpox extinct, vaccinia virus has been explored for the development of vaccines against a variety of infectious diseases. It also finds a new place in oncolytic therapy. Here we provide a brief review of the history, current status, and future prospect of vaccinia virus-based vaccine and oncolytic virus. New advancements, including a single vaccine targeting multiple viruses, strategies of arming vaccinia viruses to enhance anti-tumor activity, the promise and challenge of combining vaccinia-based virotherapy with immunotherapy, are discussed as special focus.

Keywords: Tiantan strain; Vaccinia virus; oncolytic virus; tumor; vaccine vector.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Communicable Diseases*
  • Humans
  • Immunotherapy
  • Oncolytic Virotherapy*
  • Oncolytic Viruses*
  • Vaccinia virus

Grants and funding

This work was supported by grants from 13th Five-Year National Science and Technology Major Project for Infectious Diseases [No.2017ZX10305501-002] and The Technology Service Platform for Detecting High level Biological Safety Patho-genic Microorganism Supported by Shanghai Science and Technology Commission [18DZ2293000].